Matter Intelligence | $12,000,000 | (Oct 31, 2024)
Bendi | $1,036,867 | (Oct 31, 2024)
MIND | $11,000,000 | (Oct 31, 2024)
Pathos
United States
- Chicago, Illinois
- 30/10/2024
- Series C
- $62,000,000
Pathos was borne from the belief that cancer is a collection of hundreds of rare diseases and can be best described by pathways accounting for the pathophysiology of patients. We license or co-develop clinical-stage therapeutics to ensure highly efficacious drugs are developed for the patients most likely to benefit and with significant unmet needs.
Our patient selection strategies are optimized for the fastest path to approval to improve patient outcomes as quickly as possible. Our aim is ultimately to accelerate the translation of real-world data into breakthrough therapies for patients that need them most.
- Industry Biotechnology Research
- Website https://pathos.com/
- LinkedIn https://www.linkedin.com/company/pathos-ai/
Related People
Ryan FukushimaFounder
United States -
Greater Chicago Area
Ryan has been building Tempus from the ground up, with a first principles mindset that prioritizes innovation, collaboration, and data-driven insights. Our mission to revolutionize healthcare through precision medicine has been fueled by the creation of the largest multimodal dataset in oncology, This dataset serves as the foundation for our collaborations with physicians and researchers developing next-generation treatments that can deliver better outcomes for patients.
At Tempus, we're not just focused on data harmonization - we are also dedicated to launching practical applications of AI that leverage our data advantage. With over 100PB of data, we can fuel advanced machine learning approaches to identify new insights and patterns that can drive better patient care. Our team is committed to collaborating with industry partners to develop solutions that can unlock the full potential of precision medicine, and we're excited about the possibilities that lie ahead.
Ryan was recently recognized on Endpoints News’ list of top 20 leaders under 40 in biopharma and biotech in 2023.
BondBloxx | $27,000,000 | (Oct 31, 2024)
Verax AI | $7,600,000 | (Oct 31, 2024)
Leal Therapeutics | $45,000,000 | (Oct 31, 2024)
CREW Carbon | $5,300,000 | (Oct 31, 2024)
hotglue | $4,000,000 | (Oct 31, 2024)
Third Wave Automation | $27,000,000 | (Oct 31, 2024)
Diffblue | $6,300,000 | (Oct 31, 2024)
Archon Biosciences | $20,000,000 | (Oct 31, 2024)
Avina (YC S22) | $3,200,000 | (Oct 31, 2024)